These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 22010214

  • 1. New strategies for treatment of ALK-rearranged non-small cell lung cancers.
    Sasaki T, Jänne PA.
    Clin Cancer Res; 2011 Dec 01; 17(23):7213-8. PubMed ID: 22010214
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH.
    Drug Des Devel Ther; 2011 Dec 01; 5():471-85. PubMed ID: 22162641
    [Abstract] [Full Text] [Related]

  • 5. Treatment and detection of ALK-rearranged NSCLC.
    Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R.
    Lung Cancer; 2013 Aug 01; 81(2):145-54. PubMed ID: 23769207
    [Abstract] [Full Text] [Related]

  • 6. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
    Cameron L, Solomon B.
    Drugs; 2015 Jul 01; 75(10):1059-70. PubMed ID: 26076736
    [Abstract] [Full Text] [Related]

  • 7. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N, Santarpia M, Gonzalez Cao M, Teixido C, Sosa AE, Berenguer J, Rodriguez Capote A, Altavilla G, Rosell R.
    Expert Opin Investig Drugs; 2017 Jun 01; 26(6):713-722. PubMed ID: 28463570
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.
    Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ.
    Oncologist; 2012 Jun 01; 17(11):1351-75. PubMed ID: 22989574
    [Abstract] [Full Text] [Related]

  • 10. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
    Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA.
    Cancer Discov; 2014 Jun 01; 4(6):662-673. PubMed ID: 24675041
    [Abstract] [Full Text] [Related]

  • 11. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
    Hembrough T, Liao WL, Hartley CP, Ma PC, Velcheti V, Lanigan C, Thyparambil S, An E, Monga M, Krizman D, Burrows J, Tafe LJ.
    Clin Chem; 2016 Jan 01; 62(1):252-61. PubMed ID: 26585927
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
    Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR.
    Clin Cancer Res; 2012 Mar 01; 18(5):1472-82. PubMed ID: 22235099
    [Abstract] [Full Text] [Related]

  • 13. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
    Yamaguchi N, Lucena-Araujo AR, Nakayama S, de Figueiredo-Pontes LL, Gonzalez DA, Yasuda H, Kobayashi S, Costa DB.
    Lung Cancer; 2014 Jan 01; 83(1):37-43. PubMed ID: 24199682
    [Abstract] [Full Text] [Related]

  • 14. Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.
    de Castro-Carpeño J, Perona R, Belda-Iniesta C.
    Clin Transl Oncol; 2011 Nov 01; 13(11):774-9. PubMed ID: 22082640
    [Abstract] [Full Text] [Related]

  • 15. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K, Kolesar JM.
    Am J Health Syst Pharm; 2015 Sep 01; 72(17):1456-62. PubMed ID: 26294238
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M, De Marinis F, Hirsch FR, Gridelli C.
    Int J Oncol; 2014 Aug 01; 45(2):509-15. PubMed ID: 24859689
    [Abstract] [Full Text] [Related]

  • 17. ALK in lung cancer: past, present, and future.
    Shaw AT, Engelman JA.
    J Clin Oncol; 2013 Mar 10; 31(8):1105-11. PubMed ID: 23401436
    [Abstract] [Full Text] [Related]

  • 18. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
    Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C.
    Target Oncol; 2013 Mar 10; 8(1):55-67. PubMed ID: 23325296
    [Abstract] [Full Text] [Related]

  • 19. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N.
    EBioMedicine; 2016 Jan 10; 3():54-66. PubMed ID: 26870817
    [Abstract] [Full Text] [Related]

  • 20. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A, Casaluce F, Maione P, Gridelli C.
    Expert Rev Anticancer Ther; 2018 Jan 10; 18(1):71-80. PubMed ID: 29187012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.